ENTACAPONE

ENTACAPONE
(en-ta'ca-pone)
Comtan
Classifications: catecholamine o-methyltransferase (comt) inhibitor; antiparkinson agent;
Therapeutic: antiparkinson agent

Prototype: Tolcapone
Pregnancy Category: C

Availability

200 mg tablets

Action

Selective inhibitor of catecholamine O-methyltransferase (COMT). COMT is responsible for metabolizing levodopa to an intermediate compound 3-O-methyldopa, a chemical which interferes with the availability of levodopa to the brain. Therefore, it increases availability of levodopa in CNS.

Therapeutic Effect

Taken with levodopa, it decreases the formation of 3-O-methyldopa, thus increasing the duration of the motor response of the brain to levodopa in Parkinson's disease. Effectiveness is indicated by diminished Parkinson's manifestations.

Uses

Adjunct to levodopa/carbidopa to treat Parkinson's disease.

Contraindications

Hypersensitivity to entacapone; concurrent MAO inhibitors; children; pregnancy (category D).

Cautious Use

Hepatic impairment; biliary obstruction; concomitant administration with CNS depressants; drugs metabolized by COMT (e.g., isoproterenol, epinephrine, etc.); history of hypotension or syncope; lactation.

Route & Dosage

Parkinson's Disease
Adult: PO 200 mg administered with each dose of levodopa/carbidopa up to 8 times/d

Administration

Oral
  • Give simultaneously with each levodopa/carbidopa dose.
  • Must be tapered if discontinued. Never discontinue abruptly.
  • Do not administer to patients receiving nonselective MAO inhibitors.
  • Store at 15°–30° C (59°–86° F).

Adverse Effects (≥1%)

Body as a Whole: Back pain, fatigue, asthenia. CNS: Dyskinesia, hyperkinesia, hypokinesia, dizziness, anxiety, somnolence, agitation. GI: Taste perversion, nausea, diarrhea, abdominal pain, constipation, vomiting, dry mouth, dyspepsia, flatulence, gastritis. Respiratory: Dyspnea. Skin: Increased sweating. Other: Urine discoloration, purpura.

Interactions

Drug: Extreme caution must be used if administered with a nonselective maoi; bitolterol, dobutamine, dopamine, epinephrine, isoetharine, isoproterenol, methyldopa, norepinephrine may increase heart rates, possibly cause arrhythmias, excessive changes in BP.

Pharmacokinetics

Absorption: Rapidly absorbed, 35% bioavailable. Peak: 1 h. Distribution: Highly protein bound. Metabolism: Extensively metabolized in plasma and erythrocytes. Elimination: Primarily in feces. Half-Life: 2.4 h (terminal).

Nursing Implications

Assessment & Drug Effects

  • Monitor carefully for hyperpyrexia, confusion, or emergence of Parkinson's S&S during drug withdrawal.
  • Monitor for orthostatic hypotension & worsening of dyskinesia or hyperkinesia.
  • Lab tests: Hgb and serum ferritin levels with prolonged therapy.

Patient & Family Education

  • Take with levodopa/carbidopa; not effective alone.
  • Do not discontinue abruptly; gradually reduce dosage.
  • Exercise caution when rising from a sitting or lying position because faintness/dizziness can occur.
  • Exercise caution with hazardous activities until reaction to the drug is known.
  • Harmless brownish-orange discoloration of urine is possible.
  • Report unusual adverse effects (e.g., hallucinations/unexplained diarrhea).

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

(75)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.
© 2006-2025 medpill.info Last Updated On: 04/05/2025 (0)
×
Wait 20 seconds...!!!